

Chapter 1. Introduction.....	1
1.1. Basic concepts on photochemistry.....	3
1.1.1. Photoinduced energy transfer.....	6
1.1.2. Photoinduced electron transfer.....	7
1.2. Cancer treatments nowadays.....	8
1.3. Nanomedicine.....	12
1.3.1. Viral nanoparticles.....	12
1.3.2. Organic nanoparticles.....	13
1.3.2.1. Drug conjugates.....	13
1.3.2.2. Lipid-based nanocarriers.....	13
1.3.2.3. Polymer-based nanocarriers.....	14
1.3.3. Inorganic Nanoparticles.....	14
1.4. Upconversion nanoparticles.....	15
1.4.1. Upconversion process.....	16
1.4.1.1. Excited-state absorption (ESA).....	17
1.4.1.2. Energy transfer upconversion (ETU).....	18
1.4.1.3. Photon avalanche (PA).....	18
1.4.2. UCNP composition.....	20
1.4.3. UCNP synthesis.....	22
1.4.3.1. Coprecipitation.....	22
1.4.3.2. Thermal decomposition.....	22
1.4.3.3. Hydro(solvo)termal.....	23
1.4.3.1. Ostwald-ripening.....	23
1.4.4. UCNP biomedical applications.....	24
1.4.4.1. Bioimage.....	24
1.4.4.2. Biosensing and bioassay.....	25
1.4.3.3. Therapy.....	26
1.5. Drugs for photosensitized reactions.....	26
1.5.1. Photosensitization mechanism.....	27
1.5.2. Light.....	27
1.5.3. Fluoroquinolones.....	29
1.5.3.1. Fluoroquinolones' mechanism of action.....	31
1.5.3.2. Fluoroquinolones' photogenotoxicity	32

Outline

1.6. Photosensitized release.....	32
1.6.1. Loaded drugs.....	33
1.6.2. Conjugated drugs.....	34
1.6.2.1. Coumarin-4-ylmethyl groups.....	35
1.6.2.2. <i>Ortho</i> -Nitrobenzyl groups	37
1.7. References.....	38
 Chapter 2. General objectives.....	 53
 Chapter 3. Chemical tuning for potential antitumor fluoroquinolones.....	 57
3.1. Introduction.....	59
3.2. Results and discussion.....	62
3.2.1. Absorption spectra of fluoroquinolones 1 and 2.....	62
3.2.2. Emission measurements of fluoroquinolones 1 and 2....	63
3.2.3. Laser flash photolysis studies (LFP) of fluoroquinolones 1 and 2.....	64
3.2.4. Photodegradation studies.....	68
3.2.5. Phototoxic properties.....	69
3.3. Conclusion.....	76
3.4. Experimental section.....	77
3.4.1. Materials.....	77
3.4.2. Synthesis of fluoroquinolones.....	77
3.4.3. Emission measurements.....	79
3.4.4. LFP measurements.....	80
3.4.5. Irradiation procedures and equipment.....	81
3.4.6. General procedure to identify photoproducts of 1 and 2	83
3.4.7. In Vitro 3T3 neutral red uptake (NRU) phototoxicity test.	86
3.4.8. Cellular localization studies by confocal microscopy.....	87
3.5. NMR Spectra.....	87
3.6. References.....	94

Chapter 4. Effects of fluoroquinolones structural modifications on their photosensitizing properties.....	99
4.1. Introduction.....	101
4.2. Results and discussion.....	103
4.2.1. Study of the interactions between FQ and biomolecules using emission measurements.....	103
4.2.2. Reactivity of FQ aryl cations with HSA.....	112
4.2.3. Covalent binding of FQ to HSA.....	114
4.2.4. Phototoxic properties of FQs.....	116
4.3. Conclusion.....	119
4.4. Experimental section.....	119
4.4.1. Materials.....	119
4.4.2. Synthesis of FQs.....	119
4.4.3. Absorption and emission measurements.....	120
4.4.4. Fluoroquinolone fluorescence quenching by DNA.....	120
4.4.5. Fluorescence quenching of fluoroquinolones by albumin	121
4.4.6. Albumin fluorescence quenching by fluoroquinolones....	121
4.4.7. Laser flash photolysis experiments.....	122
4.4.8. Analysis of the covalent binding of fluoroquinolones to HSA induced by light.....	123
4.4.9. <i>In Vitro</i> 3T3 neutral red uptake (NRU) phototoxicity test.	124
4.5. References.....	125
 Chapter 5. Studies of fluoroquinolone derivatives as alkylating bombs.....	131
5.1. Introduction.....	133
5.2. Results and discussion.....	135
5.2.1. Synthesis and characterization of upconversion nanoparticles (UCNP).....	135
5.2.2. Photolysis of 1 in aqueous solutions with nanosystem NaYF ₄ :Yb(20%)Tm (0.5%) @NaYF ₄ @1-SA	140
5.2.3. Cell viability assay of NaYF ₄ : Yb/Tm@NaYF ₄ @1-SA	141
5.3. Conclusions.....	142

5.4. Experimental section.....	143
5.4.1. Materials.....	143
5.4.2. Synthesis of 1-Methyl-7-dimethylamino-6,8-difluoro-1,4-dihydro-3-quinolinecarboxylic acid (1).....	143
5.4.3. Instrumentation.....	143
5.4.4. Synthesis of NaYF ₄ : Yb/Tm (20%, 0.5%)	144
5.4.5. Synthesis of NaYF ₄ : Yb/Tm (20%, 0.5%)@ NaYF ₄	144
5.4.6. Synthesis of NaYF ₄ : Yb/Tm (20%, 0.5%)@ NaYF ₄ @1-SA..	145
5.4.7 Irradiation of nanosystem NaYF ₄ : Yb/Tm (20%, 0.5%) @NaYF ₄ @1-SA.....	146
5.4.8. In Vitro HELA phototoxicity test.....	146
5.5. References.....	147
 Chapter 6. Photochemistry of photoactivable 7-Aminocoumarin derivatives.....	153
6.1. Introduction.....	155
6.2. Results and discussion.....	158
6.2.1. Photolysis of COU-DCO and COU-PHA.....	158
6.2.2. Photophysical Properties of COU-DCO and COU-PHA.....	164
6.2.2.1. Emission Properties of COU-DCO and COU-PHA.....	165
6.2.2.2. Femtosecond transient absorption spectroscopy of COU-DCO and COU-PHA.....	168
6.2.2.3. Nanosecond laser flash photolysis experiments using COU-DCO and COU-PHA.....	174
6.3. Conclusions.....	180
6.4. Experimental section.....	180
6.4.1. Materials.....	180
6.4.2. Synthesis of COU, COU-DCO and COU-PHA.....	181
6.4.3. Photolysis studies with COU-DCO and COU-PHA.....	186
6.4.4. Laser flash photolysis experiments.....	186
6.5. NMR Spectra.....	187
6.6. References.....	192

Chapter 7. Developing biocompatible upconversion nanosystems for photocontrolled drug delivery using albumin complexed with coumarin derivatives.....	197
7.1. Introduction.....	199
7.2. Results and discussion.....	201
7.3. Conclusions.....	210
7.4. Experimental section.....	211
7.4.1. Materials.....	211
7.4.2. Experimental conditions for absorption and emission measurements.....	211
7.4.3. Experimental and results of laser flash photolysis experiments.....	212
7.4.4. Experimental for drug release studies.....	213
7.4.4.1. Procedure for prodrug COU-CHB.....	213
7.4.4.2. Procedure for nanosystem UCNP@PAA@HAS…COU-CHB.....	214
7.4.5 Synthetic route and characterization of prodrug COU-CHB.....	214
7.4.6 Synthetic route and additional results for obtaining NaYF₄: Yb/Er (18%, 2%) @PAA@HSA…COU-CHB nanosystem.....	216
7.4.6.1. Synthesis of NaYF₄: Yb/ Er(18%, 2%).....	216
7.4.6.2. Surface modification of NaYF₄: Yb/Er (18%, 2%) with polyacrylic acid (PAA).....	218
7.4.6.3. Functionalization of NaYF₄: Yb/Er (18%, 2%)@PAA with Human Serum Albumin (HSA).....	219
7.4.6.4. Preparation of nanosystem NaYF₄: Yb/Er (18%, 2%) @PAA@HSA…COU-CHB.....	219
7.4.6.5. Analysis of complexation between prodrug COU or COU-CHB and HSA.....	220
7.5. NMR Spectra.....	222
7.6. References.....	224
 Chapter 8. Instrumentation.....	 229
8.1. General instrumentation.....	231

Outline

8.1.1. Nuclear magnetic resonance (NMR).....	231
8.1.2. Chromatography.....	231
8.1.2.1. Thin-layer liquid chromatography (TLC).....	231
8.1.2.2. High performance liquid chromatography.....	231
8.1.2.3. Ultra performance liquid chromatography tandem mass spectrometer (UPLC-MS/MS).....	231
8.2. Photochemical instrumentation.....	232
8.2.1. UV-VIS absorption spectroscopy.....	232
8.2.2. Time-resolved fluorescence spectroscopy.....	232
8.2.3. Steady-state photolysis.....	233
8.2.4. Laser flash photolysis spectroscopy (LFP).....	233
8.2.5. Femtosecond transient absorption spectroscopy.....	233
8.2.6. Phosphorescence emission measurements.....	235
Chapter 9. General conclusions.....	237
Chapter 10. Summary-Resumen-Resum.....	243
10.1. Summary.....	245
10.2. Resumen.....	248
10.3. Resum.....	251
Chapter 11. Scientific contribution.....	255
11.1. Contribution to Congresses.....	257
11.2. Publications.....	258